Rhythm Pharmaceuticals, Inc. (RYTM)
Rhythm Pharmaceuticals, Inc. (RYTM) is a healthcare company (biotechnology) based in the United States. The share price is $113.12, up 5.24% on the day, which values the company at $7.84B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.
Key facts
- Share price
- $113.12+5.24% today
- Market value
- $7.84B
- Funk Score
- 48/100
- Against its own history
- Well above its usual priceusual price $69.89
- 200-week average
- $61.5484% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Rhythm Pharmaceuticals, Inc. in more detail
RYTM trades at -87.1× next year's expected earnings, 27.9× sales. Measured against its own history, the price is 62% above what its usual multiples would imply ($69.89) — well above its usual price. It sits 84% above its 200-week average of $61.54.
Its Funk Score is 48 out of 100 (financial strength 6.7, profitability 2.5, growth 10.0, value 0.0, each out of 10).
In its favour: Altman Z in the safe zone; Operating margin is expanding. Worth checking: Share count keeps rising; Thin interest cover.
4 of the superinvestors tracked here hold RYTM, including Peter Kolchinsky (6.4% of the portfolio), Julian and Felix Baker (3.1% of the portfolio), Stanley Druckenmiller (0.5% of the portfolio).
Superinvestors holding RYTM
4 of the investors tracked here report a position in their latest 13F filing.
- Peter Kolchinsky RA Capital Management6.43% of portfolio · $740.2M · Q2 2026
- Julian and Felix Baker Baker Bros. Advisors3.12% of portfolio · $622.3M · Q2 2026
- Stanley Druckenmiller Duquesne Family Office0.52% of portfolio · $22.6M · new · Q2 2026
- Primecap team Primecap Management0.18% of portfolio · $291.8M · trimmed · Q3 2026
Health Care companies of similar size
- 10x GenomicsTXG
- HealthEquityHQY
- Corcept TherapeuticsCORT
- AlkermesALKS
- PACS GroupPACS
- Kiniksa Pharmaceuticals InternationalKNSA
- ImmunityBioIBRX
- CytokineticsCYTK
- ABIVAXABVX
- Bausch + LombBLCO
- Amneal PharmaceuticalsAMRX
- Caris Life SciencesCAI
Side by side:RYTM vs ALKS (Rhythm Pharmaceuticals, Inc. vs Alkermes)RYTM vs PACS (Rhythm Pharmaceuticals, Inc. vs PACS Group)RYTM vs KNSA (Rhythm Pharmaceuticals, Inc. vs Kiniksa Pharmaceuticals International)RYTM vs IBRX (Rhythm Pharmaceuticals, Inc. vs ImmunityBio)RYTM vs CYTK (Rhythm Pharmaceuticals, Inc. vs Cytokinetics)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Rhythm Pharmaceuticals, Inc. (RYTM): questions and answers
What is Rhythm Pharmaceuticals, Inc.'s market cap?
Rhythm Pharmaceuticals, Inc. is valued at $7.84B at a share price of $113.12.
Is RYTM overvalued or undervalued?
Against its own history, RYTM is well above its usual price: the price is 62% above the $69.89 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is RYTM above its 200-week moving average?
Yes. RYTM is 83.8% above its 200-week average of $61.54. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Rhythm Pharmaceuticals, Inc. growing?
Over the last three fiscal years Rhythm Pharmaceuticals, Inc.'s revenue grew 100.2% a year.
Does RYTM pay a dividend?
Rhythm Pharmaceuticals, Inc. does not currently pay a regular dividend.
Which famous investors own RYTM?
In their latest quarterly filings, Peter Kolchinsky (6.4% of the portfolio), Julian and Felix Baker (3.1% of the portfolio), Stanley Druckenmiller (0.5% of the portfolio), Primecap team (0.2% of the portfolio) hold RYTM. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Rhythm Pharmaceuticals, Inc. (RYTM) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RYTM
Underlying data: Yahoo Finance; company filings with the SEC.